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Abstract
Juvenile idiopathic arthritis (JIA) is the most common paediatric rheumatological disorder and is classified by
subtype according to International League of Associations for Rheumatology criteria. Depending on the number of
joints affected, presence of extra-articular manifestations, systemic symptoms, serology and genetic factors, JIA is
divided into oligoarticular, polyarticular, systemic, psoriatic, enthesitis-related and undifferentiated arthritis. This
review provides an overview of advances in understanding of JIA pathogenesis focusing on aetiology,
histopathology, immunological changes associated with disease activity, and best treatment options. Greater
understanding of JIA as a collective of complex inflammatory diseases is discussed within the context of
therapeutic interventions, including traditional non-biologic and up-to-date biologic disease-modifying anti-
rheumatic drugs. Whilst the advent of advanced therapeutics has improved clinical outcomes, a considerable
number of patients remain unresponsive to treatment, emphasising the need for further understanding of disease
progression and remission to support stratification of patients to treatment pathways.
Keywords: Juvenile idiopathic arthritis, Pathogenesis of juvenile idiopathic arthritis, Aetiology of juvenile idiopathic
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Introduction and classification
Juvenile idiopathic arthritis (JIA) unifies all forms of
chronic childhood arthritis, affecting not only joints, but
extra-articular structures, including eyes, skin, and in-
ternal organs, leading to disability and even associated
fatality. It is defined as the presence of arthritis of un-
known aetiology that begins before the age of 16 and
persists for at least 6 weeks [1].
The International League of Associations for Rheuma-
tology (ILAR) stratifies subtype of autoimmune inflam-
matory disorders, determined by the number of joints
affected, the presence of systemic symptoms and detec-
tion of rheumatoid factor (RF). JIA is divided into the
sub-forms: oligoarticular (persistent or extended), poly-
articular (RF-negative or RF-positive), systemic (sJIA),
psoriatic arthritis and enthesitis-related arthritis, with
each differing in genetic susceptibility and severity of
arthritis [1]. Any arthritis that does not fit into these cat-
egories or corresponds to > 1 subtype is considered as
undifferentiated [2]. The main characteristics of arthritis,
internal organ involvement, genetic predisposition, la-
boratory markers of each subtype and adult equivalent
are shown in Table 1.
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Oligoarticular JIA is characterised by inflammation of
up to four joints that archetypically proceeds as asym-
metrical arthritis predominantly affecting the joints of
the lower extremities, such as knee and ankle, with high
frequency of positivity to anti-nuclear antibody (ANA)
and high risk of chronic uveitis [3]. Polyarticular JIA
(pJIA) affects five or more large/ small joints and is hall-
marked by injury to the metacarpophalangeal joints and
wrists [4]. Both RF-positive and negative variants have
characteristic clinical features. RF-negative pJIA, inflam-
mation can be asymmetrical, but for RF-positive pJIA
symmetric involvement of the large and small joints of
hands and feet is the most prevalent. Enthesitis-related
arthritis (ERA) resembles oligoarthritis, affecting the
joints of the lower limb in association with enthesitis.
Due to the association with lower limb and sacroiliac
joints, enthesitis, uveitis and the association with HLA-
B27, Ravelli et al. (2007) have suggested ERA to be a
disease belonging to the group of spondyloarthropathies
[1]. Psoriatic arthritis often proceeds as oligoarthritis or
RF-negative polyarthritis and involves more commonly
the small joints accompanied by dactylitis, psoriatic rash
and/ or nail pitting [1, 3]. Psoriatic JIA itself is described
as a heterogeneous disease where children < 6 years are
more likely to be female, ANA-positive and predisposed
to chronic uveitis, with arthritis of wrists and small
joints of the hands and feet. In older children disease is
associated with HLA-B27 positivity, enthesitis and axial
disease with male predisposition [5].
Standing apart from other subtypes, sJIA manifests not
only with widespread joint arthritis, but also with a sig-
nificant range of systemic inflammation symptoms
(Table 1) [6]. Approximately 10% of sJIA patients
present systemic symptoms with associated macrophage
activation syndrome (MAS), a potentially life-
threatening condition with histopathological features
Table 1 The main clinical and laboratorial characteristics of JIA subtypes based on International League of Associations for
Rheumatology (ILAR) classification criteria. ANA – antinuclear antibodies, Anti-CCP – Anti-Cyclic Citrullinated Peptide, CRP - C-reactive
protein, ERA - enthesitis-related arthritis, HLA - human leukocyte antigen system, RF – rheumatoid factor, sJIA – systemic JIA
Subtype Oligoarticular
JIA
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that include the accumulation of terminally-
differentiated macrophages with high hemophagocytic
activity [7, 8]. Currently the limitations of the ILAR clas-
sification scheme are pertinent and include the absence
of link to pathogenesis, molecular pathways and re-
sponse to the therapy [9]. In addition, there is a substan-
tial unclassified cohort of patients with JIA onset before
6 years of age and female predominance having specific
features that include symmetric arthritis, iridocyclitis,
ANA and HLA-DR8-positivity. In 2019 the Pediatric
Rheumatology International Trials Organization
(PRINTO) Consensus revised the ILAR classification cri-
teria and proposed to identify this complex of features
as early-onset ANA-positive JIA [10]. Other JIA disor-
ders identified according to these preliminary criteria in-
clude sJIA, RF-positive JIA and enthesitis/spondylitis-
related JIA (Table 2). Arthritis of more than 6 weeks
duration that does not fit the criteria is grouped as
‘Other JIA’, and that fitting more than one criterion, ‘un-
classified JIA’ [10]. PRINTO Consensus highlights JIA as
not a single disease but a group of different disorders, of
which diagnosis does not require joint count or the pres-
ence of arthritis. The onset of the disease has been chan-
ged to before 18 years of age [10].
Histopathology of JIA
The main hallmark of JIA is joint inflammation with tissue
destruction [11]. Within the synovial joint, the synovial
membrane thickens in response to uncontrolled prolifera-
tion of synoviocytes and immunocompetent cells, includ-
ing T-cells, B-cells, natural killers, neutrophils,
macrophages, dendritic cells and plasma cells that infil-
trate the sub-lining layer of the synovium (Fig. 1) [11].
Hyperplasia and hypertrophy of the synovium causes
intraarticular hypoxia, increasing the production of pro-
angiogenic mediators and initiating pathological angio-
genesis [12]. Increased concentrations of vascular endo-
thelial growth factor (VEGF), a potent endothelial cell
(EC) mitogen, its soluble receptors-1 and -2 (sVEGF-R1,
sVEGF-R2), and osteopontin (OPN), a chemotactic fac-
tor that activates mononuclear cells, have been corre-
lated to synovial angiogenesis assessed by Doppler
ultrasonography of JIA patients [12]. Angiopoietin-1
(Ang-1), another pro-angiogenic EC mitogen with a role
in stabilisation of newly formed vessels was also shown
to be upregulated in JIA. New blood vessel formation
within the synovium increases blood supply and the mi-
gration of pro-inflammatory cells into the joint, forming
a pathological synovium, known as ‘pannus’ (Fig. 1).
Table 2 The preliminary criteria of the main JIA disorders proposed by the Pediatric Rheumatology International Trials Organization
(PRINTO) Consensus. The PRINTO classification proposed systemic JIA (sJIA), rheumatoid factor–positive JIA (RF+ JIA), enthesitis/
spondylitis-related JIA and early-onset antinuclear antibody–positive (early-onset ANA+) JIA. ANA – antinuclear antibodies, AOSD -
adult-onset Still’s disease, Anti-CCP – Anti-Cyclic Citrullinated Peptide, HLA - human leukocyte antigen system, RA – rheumatoid
arthritis, RF – rheumatoid factor, y.o. – years old
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sacroiliitis, or
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- history of a SpA
in relative
• Fever with exclusion of infectious, neoplastic, autoimmune,
or monogenic autoinflammatory diseases, for at least 3 days
and reoccurring over 2 weeks
+ 2 major criteria or 1 major criterion and 2 minor criteria
Major criteria:
• evanescent erythematous rash
• arthritis
Minor criteria:
- generalized lymphadenopathy and/or hepatomegaly and/or
splenomegaly
- serositis
- arthralgia lasting more than 2 weeks
Laboratory
criteria
• 2 “+” ANA tests with a
titer ≥1/160 at least 3
months apart
• 2 positive tests for
RF at least 3 months
apart or
• 1 positive test for
anti-CCP
- presence of HLA-
B27 antigen
- leukocytosis (≥ 15,000/mm3) with neutrophilia
Adult
equivalent
– RF-positive RA Spondyloarthritis AOSD
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Granulocytes, macrophages, plasma cells and lympho-
cytes accumulate in the subintima of the joint and pro-
duce pro-inflammatory mediators including tumour
necrosis factor-α (TNFα) and interleukin (IL)1β, upregu-
lating pannus-synoviocyte production of catabolic prote-
ases including matrix metalloproteinases (MMPs,
particularly MMP1 and MMP3), aggrecanases and ca-
thepsins, that breakdown the extracellular matrix of the
articular cartilage tissue causing loss of function,
biomechanical strength and the ability to smoothly ar-
ticulate the joint [2, 13]. Pro-inflammatory cytokine-
mediated activation of receptor activator of nuclear
factor-kappaB (RANK)-expressing osteoclasts results in
bone erosion [14]. Damage to cartilage and bone in the
advanced stages of JIA causes ankyloses and the loss of
movement in the affected joints. Considering that JIA is
a disease of the developing body, patients with JIA are
likely to suffer from disruption of skeletal growth [15].
Fig. 1 Schematic diagram showing the differences between the normal and JIA joint. The pathological process within the JIA synovial joint is
characterised by uncontrolled proliferation of synoviocytes resulting in increased number of layers and thickening of the synovial membrane;
rapid pathological angiogenesis; formation of pathological synovium, “pannus”, with uncontrolled growth and invasive properties; accumulation
of granulocytes, macrophages, plasma cells, lymphocytes and the production of inflammatory mediators, provoking synovitis. Created
with BioRender.com
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Aetiology
The heterogeneity of JIA disease subtypes adds complex-
ity to the investigation of cause and mechanism of
pathogenesis, and the initiating factors of JIA remain un-
resolved [16].
Environmental factors, including infectious agents,
vaccinations, antibiotics, vitamin D deficiency, stress and
trauma have been proposed as risk factors. Infectious vi-
ruses (Epstein-Barr virus, Parvovirus B, Rubivirus, Hepa-
titis B virus) and bacteria (Salmonella spp., Shigella spp.,
Campylobacter spp., S. pyogenes, B. henselae, M. pneu-
moniae, Chlamydophila pneumonia) have been reported
as causal factors provoking JIA [17]. Gastrointestinal in-
fection leading to loss of gut microbiome diversity and
disrupted tryptophan metabolism increases the risk of
ERA [18]. Carlens et al. (2009) reported that maternal
smoking during pregnancy increased the probability of
an immune imbalance during foetal development leading
to the onset and progression of paediatric arthritis [19].
In contrast, some beneficial factors such as breast feed-
ing and household siblings might decrease the risk of de-
veloping JIA [20].
Several studies have documented genetic associations
to JIA [21–25]. Genetic linkage depends on subtype and
may be divided into two groups: HLA genes and non-
HLA-related genes. Meta-analysis of genetic predispos-
ition to JIA subtypes has shown association with HLA
class II molecules (A2, DRB1, DPB1) mostly for non-
systemic subtypes (Table 1), while for sJIA the lack of
association with HLA genes has been found [21]. Oli-
goarticular JIA is associated with A2, DRB1*11,
DRB1*08, DPB1*02, DRB1*13, DRB1*15*01 and
DRB1*01, while for RF- polyarticular the most com-
monly associated genes are DPB1:03 and DRB1:08, and
for RF+ JIA, DRB1*04 and DRB1*01 [23]. Of interest,
HLA-A, HLA-B and HLA-DR were observed in females
with oligoarthritis but not males, which may point to
disease heterogeneity [2]. The main gene associated with
ERA is HLA-B27, with other genes predisposing the de-
velopment of ERA being DRB1*01, DQA1*01, and
DQB1*05 [18]. HLA-B27 is also found in late-onset
psoriatic JIA [5].Genetic pre-disposition of non-HLA-
related genes plays a pivotal role in the onset of inflam-
matory response leading to tissue damage. Genes encod-
ing cytokines TNF, IL2, IL10, IL6, macrophage
migration inhibitory factor (MIF), protein tyrosine phos-
phatase (PTPN22), signal transducer and activator of
transcription-4 (STAT4), solute carrier family-11 (pro-
ton-coupled divalent metal ion transporters), member-1
(SLC11A1), natural resistance-associated macrophage
protein-1 (NRAMP1) and WNT1-inducible signalling
pathway protein-3 (WISP3) have all been associated with
JIA [2, 21, 23]. Polymorphism in genes encoding endo-
plasmic reticulum resident aminopeptidases (ERAP1 and
ERAP2) predispose to ERA, while genes encoding IL1,
IL6, IL10 and MIF increase the risk of sJIA, which itself
is considered as a genetically distinct subtype of JIA [16].
Pathogenesis of JIA
JIA subtypes represent a heterogeneous group of dis-
eases with multifactorial and different pathogenesis
(Table 3). It is not completely understood how the com-
bination of the environmental triggers and genetic sus-
ceptibility disrupt the balance between regulatory and
effector cells in the pathogenesis of JIA.
Immunological changes
Initiation of the JIA pathophysiological cascade includes
abnormal activation of T-cells, B-cells, natural killer
(NK) cells, dendritic cells (DC), macrophages and neu-
trophils and the production of pro-inflammatory media-
tors that cause joint destruction and systemic
complications.
Oligoarticular and pJIA are characterised by autoreac-
tive antigen-specific T-cells and high titres of autoanti-
bodies, and typically shows strong associations with
MHC class II alleles. Breakdown of immunologic self-
tolerance involves MHC class II alleles suggesting a piv-
otal role for CD4+ T helper (Th) cells [21]. Inflamma-
tion is considered to be a consequence of disrupted
balance between pro-inflammatory Th1/Th17 and anti-
inflammatory regulatory T-cells (Treg). The decrease in
Treg cells is inversely correlated with an increase in the
Th17 cell population and occurs from the differentiation
of naïve T-cells by influence of IL1β [26]. Differentiation
of naive T-cells into Th-cells results in the production of
pro-inflammatory cytokine IL17, which may induce pro-
duction of IL6, MMP1 and 3, IL8 (a chemoattractant for
neutrophils) by synoviocytes, resulting in subsequent
joint destruction [16, 26]. Prelog et al. (2008) revealed
premature immunosenescence of T-cells in oligoarticu-
lar, pJIA and sJIA patients, as indicated by the loss of
compensatory proliferation of naive T-cells, increased
telomeric erosion, and loss of capability of the thymus to
produce T-cell receptor excision circles [27].
Association with HLA class II and the presence of
ANA suggests that an adaptive immune response is pre-
dominant in the pathogenesis of oligoarticular JIA. How-
ever, activated neutrophils with altered phenotype and
dysfunction, and impaired synovial monocytes and mac-
rophages with reduced capacity to phagocytose have re-
cently been identified in synovial fluid of patients with
oligoarticular JIA [28, 29]. Together with high levels of
monocyte-derived cytokines this emphasises the import-
ance of the innate immune system in oligoarticular JIA
pathogenesis [28, 29].
The pathogenesis of ERA is driven by HLA-B27-
mediated presentation of arthritogenic peptide following
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T-cell activation and IL23 and IL17 secretion. Bowel
wall inflammation usually accompanied with ERA is
driven by γδT cells, innate lymphoid cells type-3 or
Th17 cells and IL17 and IL23 production [18]. Enthesitis
is triggered by repeated biomechanical stress stimulation
resulting in microtrauma and release of fibronectin, hya-
luronan, and other molecular components from dam-
aged connective tissue, which may directly activate
synovial macrophages, stromal cells and IL23 production
to establish a positive feedback loop. Interestingly, the
pathogenesis of late-onset psoriatic JIA resembles ERA
with entheses inflammation and inflammation in the
bowel wall [5]. Early-onset psoriatic JIA is characterised
by adaptive immune mechanisms involvement with de-
velopment of dactylitis [5].
Standing apart from non-systemic subtypes that are
known as autoimmune disorders, sJIA has been suggested
to be an autoinflammatory pathology with different patho-
genesis [16]. In sJIA, uncontrolled activation of the innate
immune system results in activation of monocytes/macro-
phages, neutrophils and immature (CD34 + CD33+) mye-
lomonocytic precursors, and increased production of pro-
inflammatory cytokines IL1β, IL6, IL18 and phagocyte-
specific S100 proteins [16, 30, 31]. MAS is a complicated
sJIA, where some triggers (bacterial or viral infections,
drugs) cause uncontrolled expansion of cytotoxic CD8+
T-cells that produce pro-inflammatory cytokines and
propagate the induction and activation of hemophagocytic
macrophages that infiltrate bone marrow and multiple or-
gans in particular the liver and spleen [8].
Table 3 Differences in the pathogenesis between oligoarticular, polyarticular rheumatoid factor (RF)-negative and positive, systemic
(sJIA), psoriatic arthritis and enthesitis-related arthritis (ERA). As an autoinflammatory disease sJIA is different in pathogenesis, clinical
manifestations, and therapeutic strategy compared to non-systemic subtypes of JIA. ANA - Antinuclear antibodies, anti-MCV -
antibodies against mutated citrullinated vimentin, anti-CCP - anti-cyclic citrullinated peptide, IL - interleukin, MIF - macrophage
migration inhibitory factor, PsJIA – psoriatic JIA, RF – rheumatoid factor, sJIA – systemic JIA, TNF - tumour necrosis factor
Oligoarticular JIA Polyarticular JIA ERA Psoriatic JIA sJIA
Type of
disease
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Inflammatory cytokines
There is a significant and predominant pro-
inflammatory cytokine signature in the plasma and syn-
ovial fluid of patients with JIA. JIA patients demonstrate
high levels of TNFα, MIF, macrophage inflammatory
protein (CCL3), macrophage-derived chemokine
(CCL22), monokine induced by IFNγ (CXCL9), mono-
cyte chemoattractant protein-1 (CCL2) and IFNγ-
induced protein-10 (CXCL10) in blood and synovial
fluid [32]. Comparison of patients with different sub-
types showed significantly higher concentrations of
plasma CCL11, CXCL10 and CCL2 in oligoarticular JIA
compared to sJIA, while patients with sJIA demonstrated
higher level of IL1, IL6 and IL18 in serum [32, 33]. Ele-
vated levels of IL33 are observed in patients with RF+
polyarticular JIA in comparison with oligo- and RF+
polyarticular JIA, and are correlated with disease activity,
indicative of being a potential biomarker candidate for
pJIA disease activity [34]. The concentrations of MIF,
IL10 and IL17 in serum or synovial fluid is predictive for
oligoarticular JIA (with less than 60% accuracy). MIF,
IL17 and IL23 are also increased in ERA [18]. IL18 is
predictive for sJIA (with 93% accuracy) [32], and plays a
pivotal role in the pathogenesis of MAS, with an in-
creased concentration reported to be predictive of MAS
complication in sJIA patients [35]. Martini et al. (2012)
showed the correlation between elevated levels of pro-
inflammatory cytokine IL6 in sJIA with the severity of
joint inflammation and microcytic anaemia due to IL6
influence on erythropoiesis by increasing the synthesis
of iron-lowering hormone hepcidin [6].
Leucine-rich α2-glycoprotein (LRG), induced by pro-
inflammatory cytokines IL1, IL6 and TNFα, promotes
differentiation and proliferation of Th17 cells and is
present in the sJIA and MAS correlated with serum CRP
and ferritin levels [36]. Adenosine deaminase-2 (ADA2),
released by monocytes and macrophages following
stimulation with IL18 and IFNγ is considered to be a
novel biomarker of MAS, being strongly correlated with
ferritin, IL18 and CXCL9 [37].
Anti-inflammatory cytokines are also involved in the
progression of JIA [16]. The pleotropic effects of both
transforming growth factor-beta (TGFβ) and IL10 im-
pact on the control of innate and adaptive immunity.
Thus, TGFβ1 directly targets T-cells leading to the
established immune tolerance to self- and environmental
antigens. IL10 mediates anti-inflammatory actions by in-
duction of heme oxygenase-1, a stress-inducible protein
with anti-inflammatory properties, and through the in-
duction of mammalian target of rapamycin (mTOR) in-
hibitor [38]. Thus, the clinically inactive disease, in the
absence of medication in some patients, may represent
compensation of the autoimmune activity by anti-
inflammatory cytokines [16]. Another anti-inflammatory
cytokine, IL37 was found to be significantly elevated in
plasma and IL-37 mRNA expression has been shown to
correlate with disease activity and production of pro-
inflammatory cytokines IL6, TNFα and IL17 [39].
The collective data available to date, suggests that
cytokine patterns may be appropriate for accurate dis-
ease classification in early JIA with the potential as tar-
gets for improving diagnosis and treatment strategies for
patients with paediatric autoimmune disease [33].
Autoantibody production
Serological biomarkers in JIA patient tissues may be
stratified into those that are stable and persistent
throughout disease course (including antibodies such as
RF) and those that change over time and disease activity
(including cytokines such as IL18). ANA, RF, anti-cyclic
citrullinated peptide (anti-CCP) and antibodies against
mutated citrullinated vimentin (anti-MCV) are reported
in non-systemic JIA pathogenesis [40, 41]. RF is an anti-
body specific to the Fc portion of IgG; it was first de-
scribed as a key serological marker in patients with adult
rheumatoid arthritis (RA) and then identified in a small
sub-group of pJIA patients (only 5% of total JIA patients)
[4]. RF-positivity is associated with severe prognosis of
JIA and rapid formation of bone erosions [40]. ANA is
considered to be common for oligoarticular, polyarticu-
lar, psoriatic subtypes of JIA, and associated with in-
crease the risk of uveitis in JIA patients [42]. Anti-CCP
and anti-MCV typically characterise RF-positive pJIA
and may predict more severe and erosive disease pro-
gression needing earlier and more intensive therapy [40,
43]. Anti-CCP activates complement and macrophages
by crosslinking TLR4 and Fc gamma receptors and indu-
cing TNFα production by binding to the macrophage
Fcγ receptor IIa in vitro. Patients double positive for
Anti-CCP and RF have higher levels of TNFα, IL1β, IL6
and IL17 [41].
Establishing diagnosis and prediction of
complications
Clinical symptoms, family history, laboratory markers
and instrumental examinations (ultrasound and mag-
netic resonance imaging) are used to determine JIA sub-
type. Physical examination findings are paramount and
include signs of arthritis (pain, tenderness, stiffness and
swelling of synovial joints) and extra-articular findings
(such as rash, lymphadenopathy, dactylitis, nail changes).
Laboratory tests for HLA-B27, RF or anti-CCP antibody
identifies the subtype of JIA and the risk of bone ero-
sions and joint damage. Myeloid-related protein (MRP)8,
MRP14 and IL18 may be used as biomarkers for active
sJIA, whereas HLA-B27 is predictive of ERA [41]. ANA
and RF are useful for the diagnosis of oligo and pJIA
subtypes [41]. ANA is associated with increased risk of
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chronic non-granulomatous uveitis, which is the most
common extra-articular manifestation of JIA and is typ-
ically asymptomatic but has an elevated risk of causing
visual impairment. Aljaberi et al. (2020) reported higher
levels of pro-inflammatory calcium-binding S100 pro-
teins in sJIA patients compared to other autoinflamma-
tory syndromes. However, other studies have revealed
that high baseline S100A12 concentration is associated
with higher disease activity and response to methotrex-
ate (MTX) and anti-TNF therapy in patients with JIA in-
cluding pJIA, ERA, oligoarticular and psoriatic arthritis
[44]. Thus, S100A8/9 and S100A12 proteins are subclin-
ical inflammation markers that may help with diagnosis
and monitoring disease activity [45].
Recent history of gastrointestinal or urinary infection,
gut inflammation confirmed by elevated fecal calprotec-
tin levels, sacroiliitis with inflammatory spinal changes
and enthesitis detected by MRI support diagnosis of
ERA [18]. Subclinical gut inflammation has also been
identified in older-onset of psoriatic JIA [5].
The diagnosis of sJIA in accordance with ILAR criteria
requires arthritis and fever within the last 2 weeks, and
one of the following criteria: rash, generalised lymph-
adenopathy, enlargement of liver or spleen, or serositis
[46]. Common laboratory abnormalities suggestive of
systemic inflammation include elevated erythrocyte sedi-
mentation rate (ESR), C-reactive protein (CRP), white
blood cell count, platelet count, ferritin, transaminases,
aldolase and d-dimers help to define the activity of the
disease [47]. Laboratorial analysis of patients with active
sJIA may reveal granulocytosis, thrombocytosis, anaemia,
upregulation of acute phase reactants (elevated erythro-
cyte sedimentation rate (ESR) and C-reactive protein
(CRP), which are typical findings but not so essential for
diagnosis in comparison with the life-threatening com-
plication of MAS that include pancytopaenia, increased
levels of ferritin, liver enzymes (aspartate and alanine
transaminases), triglycerides, d-Dimers and hypofibrino-
genemia [7]. Clinical findings of MAS include high non-
remitting fever, generalised lymphadenopathy, hepatos-
plenomegaly, central nervous system dysfunction and
hemorrhagic manifestations.
Treatment
Therapeutic intervention begins at diagnosis with non-
steroidal anti-inflammatory drugs (NSAIDs) followed by
disease-modifying anti-rheumatic drugs (DMARDs, most
often methotrexate) and/or corticosteroid intra-articular
injection. In blocking prostaglandin production via inhib-
ition of cyclooxygenase-1 and cyclooxygenase-2, NSAIDs
obtain both analgesic and anti-inflammatory effects. Local
corticosteroid joint injections are effective in synovitis and
may be a first-line treatment for oligoarthritis alone or in
addition to DMARDs. Systemic administration of high
dose corticosteroids provides good short-term effect, espe-
cially in sJIA patients, but has no influence on the long-
term disease outcome. Moreover, its prolonged adminis-
tration is associated with severe side effects including
osteoporosis, growth suppression, immunosuppression
and metabolic effects (Table 4) (48).
The American College of Rheumatology (ACR) recom-
mends early use of DMARDs, specifically MTX, lefluno-
mide and/or sulfasalazine (Table 4) [48]. MTX is
considered to be the first choice DMARD for oligo- and
pJIA when NSAIDs and intraarticular steroids are insuf-
ficient [49–51]. MTX is also considered to be effective
in children with PsJIA, though the axial manifestations
limits prescription of MTX and so TNF inhibitors are
typically required in these cases [5]. Leflunomide may be
used as an alternative DMARD for pJIA in cases of
MTX intolerance [52, 53]. Sulfasalazine is recommended
for patients with moderate activity of ERA with active
peripheral arthritis, but is inefficient in case of sacroiliitis
[18, 54]. The Clinical Commissioning Policy Statement:
Biologic Therapies for the treatment of Juvenile Idio-
pathic Arthritis (2015) reports that in 30–50% of pa-
tients where disease continues to progress, advanced
biologics are the next therapeutic step.
The first biological drugs registered for the treatment
of JIA were anti-TNFα agents, etanercept and adalimu-
mab. Etanercept was approved for the treatment of pJIA
in 1999, based on a randomised, placebo-controlled
double-blind study evaluation of safety and efficacy [55].
Now TNFα inhibitors are recognized to be the most ef-
fective drugs for the treatment of JIA with influence on
pain, stiffness, growth and quality of life and were first
successful in the treatment of pJIA, then ERA, psoriatic
and oligoarthritis subtypes [48, 56, 57]. Combination of
TNFα blocking agents with MTX increases the oppor-
tunity of achieving JIA remission in patients with these
subtypes and is an effective option in uveitis-associated
JIA [58]. In a randomized double-blind trial anti-TNF
agents namely etanercept or adalimumab have proven
effective for ERA [18].
For pJIA that is nonresponsive to at least one DMARD,
including TNFα inhibitors, abatacept (CTLA4-Ig) may be
recommended [54, 59] following demonstration of long-
term efficacy, safety and improvement of quality of life in
58 JIA patients for 7 years [59]. Another option should
TNFα inhibition reach sub-optimal clinical outcomes for
pJIA is the IL6 receptor inhibitor, tocilizumab. Toci-
lizumab might also be a treatment option for JIA-related
uveitis refractory to MTX and TNF inhibitors [60].
For many years anti-TNFα therapy demonstrated im-
proved treatment outcomes for all forms of JIA but were
less effective for sJIA, where the therapeutic approach
has been IL1β/IL6 signalling blockade [56, 61–63]. Toci-
lizumab (anti-IL6R) was the first approved medication
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Table 4 The mechanism of action and side effects of commonly used medications for JIA treatment. DMARDs - disease-modifying
anti-rheumatic drugs, GC – glucocorticoids, ERA - enthesitis-related arthritis, IL - interleukin, NK - natural killer, MAS – macrophage
activation syndrome, MTX – Methotrexate, sJIA – systemic JIA, TNF - tumor necrosis factor
Drug Mechanism of Action Therapeutic Options Adverse Event Reference
Non-Biologic DMARDs
MTX • MTX is a structural analogue of folic
acid that inhibits dihydrofolate
reductase and DNA synthesis• Acts
in different pathway: cytokine
production, arachidonic acid
metabolism and cell apoptosis
• Polyarticular JIA• Oligoarticular JIA•
JIA-related uveitis refractory to top-
ical treatment• sJIA with predomin-
ant joint inflammation and without
active systemic symptoms• Psoriatic
JIA
• Nausea• Oral ulceration• Infections
(herpes zoster)• Severe






Leflunomide • Inhibition of T-cell proliferation by
blocking pyrimidine synthesis
• Polyarticular JIA patients who
cannot tolerate MTX• Used rarely in
pediatric patients because of its
teratogenicity and long half-life




Sulfasalazine • Immune-suppressive effect not fully
established
• ERA with moderate activity, but not










Adalimumab • Subcutaneous recombinant human
IgG1κ monoclonal antibody•
Neutralises TNFα by binding with
soluble and membrane-bound TNF
• JIA patients with resistance or
intolerance to MTX• Polyarticular
JIA• JIA with uveitis• ERA refractory
to sulfasalazine• Psoriatic JIA
• Risk of reactivation of latent
infections such as tuberculosis, and
new infections caused by viruses,
fungi, or bacteria• Rare reports of:-
Lymphoma- Demyelinating central
nervous system disorders- Cardiac
failure
[58]
Infliximab • Intravenous chimeric monoclonal
antibody against TNFα• Binding with
soluble and transmembrane TNFα,
that mediates complement and
antibody-dependent cytotoxicity of
expressed TNFα cells (macrophages
and monocytes)
• Polyarticular JIA where there has
been the use of MTX for at least 3
months with poor response•
Uveitis• Psoriatic JIA
• Opportunistic infections: herpes,
tuberculosis, pseudomonas
pneumonia, reactivation of hepatitis
B, fungal infection
[56, 57]
Etanercept • Fusion protein consisting of the
extracellular domain of the human
p75 TNFα receptor• Linked to the Fc
region of human IgG1, binds and
inhibits soluble TNFα
• Polyarticular JIA with resistance or
intolerance to MTX• ERA• Psoriatic
JIA





Anakinra • Recombinant IL1 receptor
antagonist binds to IL1 receptors
(IL1r1)• Inhibits the binding of IL1α
and IL1β
• Refractory sJIA with persistent
systemic symptoms• MAS
- Vomiting, nausea, diarrhea-
Headache- Abdominal pain- Upper
respiratory and urinary tract
infections- Neutropenia
[61, 63]
Canakinumab • Human Monoclonal antibody•
Selectively blocks IL1β
• sJIA patients with continued
disease activity after treatment with




Upper respiratory tract infection•
Cough• Abdominal pain•
Gastroenteritis, vomiting, diarrhea•
Pyrexia• Very rare:- pneumococcal
sepsis
[64]
Rilonacept • Fusion protein between the Fc
portion of IgG and the IL1 receptor•
Blocks the interaction of IL1 with
cell surface receptors preventing IL1
signalling
• Active sJIA • Infections• Developed elevations in
liver transaminases• High cholesterol




Abatacept • Inhibitor of naïve T-cell activation•
Soluble fusion protein of CTLA-4
with the Fc portion of IgG that
• Severe sJIA• Polyarticular JIA
patients with inadequate response
to MTX and TNF-blockers
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for the treatment of active sJIA, demonstrating safety
and efficacy in two multicentre studies of patients with
sJIA and pJIA [31]. Other studies have shown the effi-
cacy of IL1 blockade in sJIA [61]. Complete remission
was obtained in seven out of nine patients with refrac-
tory sJIA treated with recombinant IL1 receptor antag-
onist anakinra (the other two patients demonstrating a
partial treatment response) [62]. However, Quartier
et al. (2011) reported a short-term effect of this drug in
corticosteroid-dependent patients with sJIA in a rando-
mised, double-blind, placebo-controlled trial and showed
that anakinra is less effective on arthritis than on sys-
temic symptoms [63]. Currently, anakinra (IL1Ra), rilo-
nacept (IL1 inhibitor) and canakinumab (anti-IL1β) have
been successfully studied in clinical research with com-
parable long-term efficacy where half of treated patients
achieved remission [61, 64–67]. IL18 may be another
target for treatment of sJIA resistant to IL1 and IL6
Table 4 The mechanism of action and side effects of commonly used medications for JIA treatment. DMARDs - disease-modifying
anti-rheumatic drugs, GC – glucocorticoids, ERA - enthesitis-related arthritis, IL - interleukin, NK - natural killer, MAS – macrophage
activation syndrome, MTX – Methotrexate, sJIA – systemic JIA, TNF - tumor necrosis factor (Continued)
Drug Mechanism of Action Therapeutic Options Adverse Event Reference
binds to CD80/CD86 and blockades
signal following MHC-peptide: TCR
engagement necessary for T cell
activation
IL6 inhibitors
Tocilizumab • Humanised monoclonal antibody
against the IL6 ubiquitous receptor
(IL-6R)• Block IL6 signaling pathway
by binding to cell-surface and sol-
uble IL-6R
• sJIA• Polyarticular JIA with
resistance and continued disease
activity after treatment with MTX
and TNF-blockers
• Headache• Upper respiratory tract






Rituximab • Chimeric monoclonal antibody
against B-cells with mouse variable
and human constant regions• Binds
CD20 on the surface of B-cells form-
ing a cap that allow NK cells to des-
troy B cells• Leads to B-cell death
and removal from circulation
• JIA refractory to anti-TNF agents
and standard immunosuppressive
therapy
• Infusion reactions (headache, throat
irritation, rash, itchiness, pyrexia) in
one third of patients• Bacterial
infections• Hepatitis B reactivation•





Janus Kinase (JAK) inhibitors
Tofacitinib • Inhibit JAK1 and JAK3• Interrupt the
JAK-STAT signalling pathway, which
is responsible for the transmission of
extracellular multiple proinflamma-
tory cytokines, including IL-6, into
the nucleus, leading to changes in
DNA transcriptome
• Refractory polyarticular JIA• sJIA
refractory to other therapy
• Diarrhea• Headache• High blood
pressure• Upper respiratory tract
infections• Varicella zoster virus
reactivation• Cytomegalovirus
infection• Pulmonary embolism•






• Binding to glucocorticoid receptors
inhibits calcium and sodium cycle
across plasma membranes, reducing
activation and proliferation of
immune cells• Post-transciptional
destabilisation of messenger RNA
resulting in reduced production of
proinflammatory cytokines including
IL1 and IL6
√ Systemic steroids for:• sJIA with
serious organ involvement (including
pericarditis, myocarditis)• Patients
with features indicative of MAS• High
disease activity in oligo- and
polyarticular JIA• Intraarticular






Gastric ulcer• Cataract• Glaucoma
[48]
Cyclosporine A • A fungal cyclic polypeptide• Binds to
the cellular protein cytophilin,




the G0-G1 phase of the cell cycle•
Then inhibits IL2 production and re-
lease by T-helpers
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inhibition, as far as higher levels of IL18 have been asso-
ciated with high ferritin levels reported in MAS [68, 69].
MAS as a form of hemophagocytic lymphohistiocytosis
is usually treated with high-dose methylprednisolone
and cyclosporine A (a calcineurin inhibitor). In relation
to biological therapies, treatment of MAS has been suc-
cessful using IL1 receptor antagonist anakinra (IL-1Ra)
and rituximab (anti-CD20) [70], which has also demon-
strated efficacy in other immunological disorders, in-
cluding SLE [61]. Other promising therapeutics,
tadekinig alfa (anti-IL18) and emapalumab (anti-IFNγ)
are currently undergoing clinical trials with data report-
ing safety and potential efficacy for the treatment of sJIA
and MAS [71, 72].Another new class of biological
DMARDs are the Janus-associated tyrosine kinases
(JAK) inhibitors. The mechanism of their action consists
of blocking JAK-STAT pathways to interrupt the trans-
duction of extracellular pro-inflammatory signals into
the cell nucleus. The efficacy of first generation of JAK
inhibitors (namely tofacitinib and baricitinib) were first
explored in adults with RA, and then in other immune-
mediated inflammatory diseases such as ankylosing
spondylitis, SLE, inflammatory bowel disease and psoria-
sis [73]. Tofacitinib was effectively used in case of refrac-
tory sJIA [74]. Miserocchi et al. (2020) showed
effectiveness of tofacitinib and baricitinib in 4 cases of
JIA uveitis, defined by a reduction of intraocular inflam-
mation according to Standardized Uveitis Nomenclature
criteria, and no side effects were registered [75]. The re-
sults of a randomised phase 3, multinational, double-
blind, controlled clinical trial (NCT02592434) has
proven the safety and effectiveness of tofacitinib in pJIA,
resulting in reduced flares and disease activity [76]. On-
going trials are investigating baricitinib (NCT04088396,
NCT03773978, NCT04088409) and tofacitinib (NCT03
000439) in patients with other JIA disorders [77].Recent
therapeutic advances including combination of DMAR
Ds, corticosteroids and the biological agents reduce
synovitis, tissue damage progression and systemic com-
plications, making low disease activity an achievable goal
in JIA. Early treatment with biologics may be important
in controlling disease activity and avoiding steroids
altogether or at least reducing the duration of use. How-
ever, long-term prescription of biologic agents due to
immune suppression increases the risk of opportunistic
infections and potentially even malignancy (the main ad-
verse events are shown in the Table 4) [56]. Early ag-
gressive treatment of JIA was shown to be beneficial
with 40% of patients achieving clinical inactive disease
within 6 months [78], though some serious adverse
events was registered during treatment (such as pneu-
monia, septic joint, elevation of transaminases, periton-
sillar abscess, recurrent herpes simplex). It may be
suggested that some of these patients would have
achieved remission even with less aggressive treatment
[79].
Disease course, quality of life and functional
outcome
Substantial progress in JIA treatment has been made
over the last three decades. Clinical outcomes have dra-
matically improved, with disease control and remission
possible in most patients. Nevertheless, a significant pro-
portion of patients have ongoing disease activity. In fact,
about half of patients continue to require active treat-
ment into adult life, whereas complete remission is
achieved in only 20–25% of patients [80, 81].
Administration of biological agents has decreased
the mortality rate of JIA from 1 to 4% in 1970s to
0.3–1% in 2016 [82]. Improved clinical outcomes in
physical disability are reflected in the Steinbrocker
functional classification scale. Between 1976 and 1994,
15% of JIA patients were within Class III (limited to
few or no activities of the patient’s usual occupation)
and Class IV (bedridden with little or no self-care),
compared to 5% in 2002 [83]. However, joint damage,
occurring before treatment led to surgical intervention
in 14% of patients, emphasising the importance of
early aggressive treatment to achieve complete remis-
sion [84]. The prominent factor influencing treatment
outcome is presence of systemic manifestation. Multi-
organ failure in patients with MAS is fatal in approxi-
mately 8% of cases [8].
Being the most frequent extraarticular manifestation
JIA-associated uveitis became the main cause of vision
loss in childhood, and furthermore about half of these
patients suffer from active uveitis in adulthood [85].
Additionally, a high risk of osteoporosis and conse-
quently fractures in early adulthood remain higher in
JIA patients even in remission [15].
Long-term outcomes of JIA patients are dependent on
subtype and disease activity, which may remain elevated
for many years including into adulthood. In early adult-
hood about half of patients with JIA have active disease
and approximately 30% suffer from some form of dis-
ability [80]. Selvaag et al. (2016) reported a 59% remis-
sion rate in patients with JIA after 30 years but noted
the low quality of life in adults with JIA [81].
Comorbidities and complications highlight the status
of JIA as the most important paediatric rheumatological
pathology that may continue with remissions and flares
throughout life, leading to impairment of connective tis-
sue and the reduction of life quality. There is a need for
more discovery science research to help the understand-
ing of the complexity of the inflammatory process and
to enable the development of treatments that may come
with the promise of an actual cure.
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Conclusions
JIA is a chronic rheumatic disease of childhood, charac-
terised by progressive joint destruction and serious sys-
temic manifestations. Complex interactions between
immune cell populations, including lymphocytes, mono-
cytes, macrophages and neutrophils, trigger the patho-
physiological cascade in JIA. Our review of clinical
research has demonstrated that the heterogeneity of
non-systemic and sJIA pathogenesis stratifies JIA pa-
tients by subtype, with requirement for differing thera-
peutic approaches. A broad range of DMARDs such as
T-cell inhibitors, anti-TNFα agents, IL1 and IL6
blockers, JAK inhibitors have significantly improved the
clinical management of JIA. However, further research is
needed to deepen our understanding of the complexity
of the inflammatory process in JIA and to enable the de-
velopment of effective treatments that improve upon
clinical outcomes and disease remission.
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